Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)

US National Institutes of Health (NIH) grant open #PAR-25-064

Response due Sep 07, 2026 · 00:00 UTC

Summary

This NIH funding opportunity (PAR-25-064) solicits exploratory/developmental research (R21 mechanism) investigating novel biological, psychological, or other mechanisms underlying neuropsychiatric symptoms (NPS) in Alzheimer's disease and related dementias. Clinical trials are optional under this announcement. The program aims to advance understanding of NPS etiology and potential intervention targets in Alzheimer's dementia populations. Proposals will be accepted on a rolling basis through September 2026.

How they evaluate

Submission: Grants.gov federal grants portal (electronic submission)

Risks & flags

Minimal scope detail provided in synopsis — full FOA (PAR-25-064) must be reviewed for hidden specificity or restrictive eligibility criteria
Long open window (Nov 2024 – Sep 2026) with rolling submissions may mask preferred review cycles

Market context

inferred from NAICS

Professional, Scientific & Technical Services

NAICS 541711

US market size: $2.0T
Typical award: $25K – $50M

Typical buyers

All federal civilianDoDStates

Commonly required

8(a)WOSBSDVOSBPE/PMP

Sector-level estimate — full code lookup not yet in catalog.

Novel Mechanism Research on Neuropsychiatr…

Due Sep 07

Onboard ↗